AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7648782 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor metabolic control (increase of HbAlc% levels)
Number of subjects: 46
Study 7648782 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration of metabolic control
Number of subjects: 46
Study 7648782 — intervention group
Group type: COMPARATOR
Intervention: Aging and duration of diabetes mellitus
Number of subjects: 46
Study 3555607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lenses
Number of subjects: 0
Study 3555607 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 0
Study 31312963 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic system
Number of subjects: 112
Study 31312963 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopic system
Number of subjects: 112
Study 29688172 — intervention group
Group type: EXPERIMENTAL
Intervention: nBDP 100 μg per nostril twice daily
Number of subjects: 34
Study 27482087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin (IN-OT)
Number of subjects: 320
Study 27482087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 24736243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate care clinics for diabetes (ICCDs)
Number of subjects: 1997
Study 24736243 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1997
Study 24399583 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitive cardiac troponin-I (HsTn-I) in patients with SCF pattern
Number of subjects: 97
Study 24399583 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery disease (CAD) group
Number of subjects: 97
Study 24399583 — intervention group
Group type: COMPARATOR
Intervention: Normal coronary arteries
Number of subjects: 97
Study 20682502 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (VSL #3 and Lactobacillus casei DN‐114 001)
Number of subjects: 0
Study 19794200 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting intervention
Number of subjects: 104
Study 16169430 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 0
Study 16169430 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12505733 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse paddle orientation
Number of subjects: 20
Study 12505733 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal paddle orientation
Number of subjects: 20
Study 10389843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk formula feeding
Number of subjects: 200
Study 10389843 — intervention group
Group type: COMPARATOR
Intervention: Exclusively breast-fed
Number of subjects: 200
Study 10389843 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with at least two diabetes‐associated autoantibodies
Number of subjects: 200
Study 10389843 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic children
Number of subjects: 200
Study 10389843 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 200
Study 8677586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of PGE1 at a speed of 60 seconds
Number of subjects: 11
Study 8677586 — intervention group
Group type: COMPARATOR
Intervention: Intracavernous injection of PGE1 at a speed of 5 seconds
Number of subjects: 11
Study 1799761 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-F catheter
Number of subjects: 499
Study 1799761 — intervention group
Group type: COMPARATOR
Intervention: 7-F catheter
Number of subjects: 499
Study 6872421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 120
Study 6872421 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomepirac 100 mg
Number of subjects: 120
Study 6872421 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 120
Study 6872421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31362753 — intervention group
Group type: EXPERIMENTAL
Intervention: H2GO! intervention (community-based youth empowerment intervention)
Number of subjects: 110
Study 31362753 — intervention group
Group type: COMPARATOR
Intervention: Standard programming (control group)
Number of subjects: 110
Study 28558702 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 U/kg AVP under P/R anaesthesia
Number of subjects: 60
Study 28558702 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 U/kg AVP under S/N anaesthesia
Number of subjects: 60
Study 28558702 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus of saline under P/R anaesthesia
Number of subjects: 60
Study 28558702 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus of saline under S/N anaesthesia
Number of subjects: 60
Study 26921128 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple debridement (Deb)
Number of subjects: 86
Study 26921128 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps tenotomy (BTo)
Number of subjects: 86
Study 26921128 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps tenodesis (BTd)
Number of subjects: 86
Study 22925188 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 130
Study 22925188 — intervention group
Group type: COMPARATOR
Intervention: Traditional closed drainage (TCD)
Number of subjects: 130
Study 22925188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VAC and TCD
Number of subjects: 130
Study 22488817 — intervention group
Group type: EXPERIMENTAL
Intervention: Management with urodynamics (N = 31)
Number of subjects: 59
Study 22488817 — intervention group
Group type: COMPARATOR
Intervention: Management without urodynamics (N = 28)
Number of subjects: 59
Study 19224304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (40 mg intravenous)
Number of subjects: 50
Study 19224304 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50
Study 17684992 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorane (4 ml/kg body weight) administered within the first 24 hours after injury
Number of subjects: 65
Study 17684992 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 65
Study 15147801 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 M lactose as carrier for FK888 dry powder inhaler (DPI)
Number of subjects: 0
Study 15147801 — intervention group
Group type: COMPARATOR
Intervention: Various carrier lactoses (100 M, 325 M, 200 M, 450 M, micronized lactoses)
Number of subjects: 0
Study 15147801 — intervention group
Group type: COMPARATOR
Intervention: Micronized lactoses (MLs)
Number of subjects: 0
Study 11318913 — intervention group
Group type: EXPERIMENTAL
Intervention: Announced standardized patient-instructors (SPIs)
Number of subjects: 24
Study 11318913 — intervention group
Group type: EXPERIMENTAL
Intervention: Unannounced standardized patient-instructors (SPIs)
Number of subjects: 24
Study 9815809 — intervention group
Group type: EXPERIMENTAL
Intervention: 1, 2, or 4 mg of aluminum hydroxide-precipitated 3H1 anti-idiotype antibody every other week for four injections and then monthly until tumor progression.
Number of subjects: 24
Study 8185457 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated group exercise
Number of subjects: 55
Study 8185457 — intervention group
Group type: COMPARATOR
Intervention: Group reminiscence therapy
Number of subjects: 55
Study 8185457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (exercise and reminiscence)
Number of subjects: 55
Study 2897515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single intramuscular dose)
Number of subjects: 0
Study 2897515 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (four doses in two days)
Number of subjects: 0
Study 30783823 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (monthly data download from insulin pumps and glucometers, immediate phone feedback, face-to-face visits every 6 months)
Number of subjects: 74
Study 30783823 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 74
Study 30783823 — intervention group
Group type: COMPARATOR
Intervention: Standard care (routine care with face-to-face visits every 3 months)
Number of subjects: 74
Study 30783823 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 74
Study 27921216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination induction task
Number of subjects: 41
Study 27921216 — intervention group
Group type: COMPARATOR
Intervention: Distraction condition
Number of subjects: 41
Study 27057904 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP titration
Number of subjects: 50
Study 27057904 — intervention group
Group type: COMPARATOR
Intervention: Control group PEEP (10 cm H2O)
Number of subjects: 50
Study 24372443 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care based on the Theory of Human Caring
Number of subjects: 105
Study 24372443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 105
Study 22747353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic splinting
Number of subjects: 52
Study 22747353 — intervention group
Group type: COMPARATOR
Intervention: Static splinting
Number of subjects: 52
Study 19076790 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 MU IFN-alpha2a
Number of subjects: 53
Study 19076790 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 53
Study 17329698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment
Number of subjects: 120
Study 17329698 — intervention group
Group type: COMPARATOR
Intervention: Community-based periodontal care
Number of subjects: 120
Study 15309972 — intervention group
Group type: EXPERIMENTAL
Intervention: PDRN eye drops
Number of subjects: 60
Study 15309972 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 60
Study 11283440 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 27
Study 11283440 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 27
Study 11283440 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose capsules)
Number of subjects: 27
Study 9883463 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with more advanced DAT (mildly demented)
Number of subjects: 0
Study 9883463 — intervention group
Group type: COMPARATOR
Intervention: Very mildly impaired patients with DAT
Number of subjects: 0
Study 9883463 — intervention group
Group type: COMPARATOR
Intervention: Healthy older adults
Number of subjects: 0
Study 7608354 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential therapy using Gestalt empty‐chair dialogue intervention
Number of subjects: 34
Study 7608354 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo condition (psychoeducational group)
Number of subjects: 34
Study 2239758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish diet (200 g lean Australian fish flesh/d)
Number of subjects: 12
Study 2239758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish diet supplemented with 5 g fish oil/d
Number of subjects: 12
Study 2239758 — intervention group
Group type: COMPARATOR
Intervention: Control diet (essentially fish free)
Number of subjects: 12
Study 908151 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral metoclopramide
Number of subjects: 4
Study 908151 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral metoclopramide
Number of subjects: 4
Study 908151 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral metoclopramide
Number of subjects: 4
Study 908151 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral metoclopramide
Number of subjects: 4
Study 908151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31521847 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 199
Study 31521847 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 199
Study 28632543 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV guidance
Number of subjects: 42
Study 28632543 — intervention group
Group type: COMPARATOR
Intervention: CVP guidance
Number of subjects: 42
Study 25477161 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate (5 mg)
Number of subjects: 244
Study 23993772 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 367
Study 23993772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac index
Number of subjects: 367
Study 23993772 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP and cardiac index association
Number of subjects: 367
Study 23993772 — intervention group
Group type: COMPARATOR
Intervention: Fluid management protocols (liberal or conservative)
Number of subjects: 367
Study 21176086 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg oral misoprostol (n = 534)
Number of subjects: 1119
Study 21176086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 585)
Number of subjects: 1119
Study 19409861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 0
Study 19409861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 0
Study 19409861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 0
Study 19409861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17725473 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised suctioning procedure followed by a standardised recruitment manoeuvre.
Number of subjects: 48
Study 17725473 — intervention group
Group type: COMPARATOR
Intervention: Control group received only the single suctioning procedure.
Number of subjects: 48
Study 15465075 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccination
Number of subjects: 26
Study 15465075 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 26
Study 11842906 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-N load with oscillation
Number of subjects: 30
Study 11842906 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-N static load
Number of subjects: 30
Study 11842906 — intervention group
Group type: COMPARATOR
Intervention: 100-N static load
Number of subjects: 30
Study 9725663 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐monoglyceride
Number of subjects: 6
Study 9725663 — intervention group
Group type: EXPERIMENTAL
Intervention: triglyceride
Number of subjects: 6
Study 7981845 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging at an intensity of 75% VO2max (n = 28)
Number of subjects: 75
Study 7981845 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at an intensity of 50% VO2max (n = 28)
Number of subjects: 75
Study 7981845 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging (n = 28)
Number of subjects: 75
Study 7981845 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (n = 28)
Number of subjects: 75
Study 7981845 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (n = 19)
Number of subjects: 75
Study 2247718 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of correlation between GFR and inverse serum creatinine slopes
Number of subjects: 0
Study 603217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 22
Study 603217 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative physiotherapy (Control)
Number of subjects: 22
Study 31586377 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise based on the FITT protocol for 8 weeks
Number of subjects: 86
Study 28556284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil plus α1-blocker combination therapy
Number of subjects: 171
Study 28556284 — intervention group
Group type: COMPARATOR
Intervention: α1-blocker monotherapy
Number of subjects: 171
Study 25790672 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiangji Recipe (QR) + Celecoxib Capsule (0.2 g, twice daily)
Number of subjects: 54
Study 25790672 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib Capsule (0.2 g, twice daily)
Number of subjects: 54
Study 23498169 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose (300 mg)
Number of subjects: 33
Study 16467122 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 9000
Study 16467122 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 9000
Study 16467122 — intervention group
Group type: COMPARATOR
Intervention: Combination of Anastrozole and Tamoxifen
Number of subjects: 9000
Study 12732606 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment of LV size and function
Number of subjects: 263
Study 12732606 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year assessment of LV size and function
Number of subjects: 263
Study 12732606 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years assessment of LV size and function
Number of subjects: 263
Study 12732606 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LV size and function from baseline to 2 years
Number of subjects: 263
Study 12732606 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors and beta‐adrenergic receptor blockers
Number of subjects: 263
Study 10528024 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg)
Number of subjects: 29133
Study 10528024 — intervention group
Group type: COMPARATOR
Intervention: beta-carotene (20 mg)
Number of subjects: 29133
Study 10528024 — intervention group
Group type: COMPARATOR
Intervention: both alpha-tocopherol and beta-carotene
Number of subjects: 29133
Study 10528024 — intervention group
Group type: COMPARATOR
Intervention: neither alpha-tocopherol nor beta-carotene
Number of subjects: 29133
Study 8702250 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm-modulated rate of carboplatin (CBDCA)
Number of subjects: 24
Study 8702250 — intervention group
Group type: COMPARATOR
Intervention: Constant rate of carboplatin (CBDCA)
Number of subjects: 24
Study 1705258 — intervention group
Group type: EXPERIMENTAL
Intervention: Two boluses of GH (2 units administered iv)
Number of subjects: 6
Study 1705258 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight boluses of GH (2 units administered iv)
Number of subjects: 6
Study 1705258 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant infusion of GH (2 units administered iv)
Number of subjects: 6
Study 1705258 — intervention group
Group type: EXPERIMENTAL
Intervention: All GH study protocols
Number of subjects: 6
Study 1705258 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant infusion of GH
Number of subjects: 6
Study 6667034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead chelating agent
Number of subjects: 0
Study 30974489 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 2961
Study 30974489 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2961
Study 27072591 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-enriched dairy drink (400 mL/day, ±400 mg EPA-DHA/day)
Number of subjects: 110
Study 25125457 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg solanezumab every 4 weeks for 18 months
Number of subjects: 1314
Study 25125457 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 18 months
Number of subjects: 1314
Study 22677919 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference normal sleep night (RN)
Number of subjects: 12
Study 22677919 — intervention group
Group type: COMPARATOR
Intervention: Partial sleep deprivation (PSD)
Number of subjects: 12
Study 21636120 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 107
Study 21636120 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 10 μg
Number of subjects: 107
Study 21636120 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg and 10 μg
Number of subjects: 107
Study 21636120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 19330891 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication supply classification (undersupply, appropriate supply, oversupply)
Number of subjects: 562
Study 19330891 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 562
Study 19330891 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication acquisition measures
Number of subjects: 562
Study 16802768 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 88 microg twice daily
Number of subjects: 332
Study 16802768 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 44 microg twice daily
Number of subjects: 332
Study 16802768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chlorofluorocarbon propellant alone)
Number of subjects: 332
Study 12954519 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonale, 91-day extended cycle oral contraceptive (30 microg ethinyl estradiol / 150 microg levonorgestrel)
Number of subjects: 0
Study 12954519 — intervention group
Group type: COMPARATOR
Intervention: Nordette-28, conventional 28-day oral contraceptive (30 microg ethinyl estradiol / 150 microg levonorgestrel)
Number of subjects: 0
Study 10740557 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram kg‐1 bolus over 30 s and infusion at 0.5 microgram kg‐1 min‐1 with glycopyrolate 200 micrograms
Number of subjects: 60
Study 10740557 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 microgram kg‐1 bolus over 30 s and infusion at 0.25 microgram kg‐1 min‐1 with glycopyrolate 200 micrograms
Number of subjects: 60
Study 10740557 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 0.5 microgram kg‐1 bolus over 30 s and infusion at 0.25 microgram kg‐1 min‐1 without glycopyrolate
Number of subjects: 60
Study 8623106 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside 300 mg intravenously, two doses before surgery
Number of subjects: 29
Study 8623106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 29
Study 8623106 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside
Number of subjects: 29
Study 1594898 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 ml of 100% alcohol/kg body weight)
Number of subjects: 36
Study 1594898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36